Advertisement
Advertisement
U.S. markets open in 4 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioVaxys Technology Corp. (BVAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0900-0.0022 (-2.44%)
At close: 01:28PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0922
Open0.0891
BidN/A x N/A
AskN/A x N/A
Day's Range0.0891 - 0.0900
52 Week Range0.0616 - 0.3800
Volume4,971
Avg. Volume48,987
Market Cap8.035M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BVAXF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BIOVAXYS TECHNOLOGY CORP
    Analyst Report: Waste Management, Inc.Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • ACCESSWIRE

    The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News

    The Power Play by The Market Herald has announced the release of a new interview with BioVaxys Technology discussing their latest news.

  • PR Newswire

    BioVaxys Further Expands Vaccines Intellectual Property Portfolio

    BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the patent coverage for its viral vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") for BVX-1021, it's vaccine for SARS1 and other sarbecoviruses.

  • CNW Group

    BIOVAXYS CLOSES FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

    BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of its previously announced non-brokered private placement (the "Private Placement"). Pursuant to the Final Tranche of the Private Placement, the Company has issued 1,350,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $135,000. Including the first tranche of the Private Placement which completed on August

Advertisement
Advertisement